RPRX

Earnings Decline: Royalty Pharma plc reported a profit drop in the third quarter, with earnings of $288.22 million ($0.67 per share) compared to $543.99 million ($1.21 per share) last year.

Revenue Increase: Despite the decline in earnings, the company's revenue increased by 7.9% to $609.29 million, up from $564.69 million in the previous year.

Third Quarter Financial Performance: Royalty Pharma plc reported a decline in net income to $288 million for Q3 2025, down from $544 million the previous year, attributed to higher operating expenses and provisions.

Revenue and Operating Income: Total revenue increased slightly to $609 million, driven by higher income from financial royalty assets, while operating income fell to $427 million due to increased expenses.

Royalty Receipts Growth: Royalty Receipts grew by 11% to $811 million, with significant contributions from products like Voranigo and Tremfya, and Portfolio Receipts also increased by 11% to $814 million.

Revised Full-Year Outlook: The company raised its full-year Portfolio Receipts forecast to between $3.2 billion and $3.25 billion, indicating expected growth of 14% to 16%.

Royalty Pharma Acquisition: Royalty Pharma has acquired a 1% royalty interest in Alnylam's AMVUTTRA for $310 million from Blackstone Life Sciences, which stems from a previous financing collaboration to support AMVUTTRA's clinical trials.

AMVUTTRA Overview: AMVUTTRA is an FDA-approved RNAi therapeutic for treating ATTR amyloidosis, a serious disease caused by misfolded proteins, and has shown significant commercial growth, with sales projected to exceed $6 billion by 2028.

Transaction Details: The royalty acquired will last until March 2035, and the sales from AMVUTTRA will begin on October 1, 2025, excluding prior fixed payments made to Blackstone.

Company Backgrounds: Royalty Pharma is a leading buyer of biopharmaceutical royalties, while Blackstone Life Sciences focuses on investing in life sciences to bring new medicines to market, managing $12 billion in assets.